References
- Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004;57:121–6. doi: 10.1046/j.1365-2125.2003.01875.x
- Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging 2014;9:2079–86. doi: 10.2147/CIA.S71178
- US Food and Drug Administration. Preventable Adverse Drug Reactions: A Focus on Drug Interactions 2018 [displayed 30 December 2020]. Available at https://www.fda.gov/drugs/drug-interactions-labeling/preventable-adverse-drug-reactions-focus-drug-interactions
- Malki MA, Pearson ER. Drug-drug-gene interactions and adverse drug reactions. Pharmacogenomics J 2020;20:355–66. doi: 10.1038/s41397-019-0122-0
- Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics 2014;15:655–65. doi: 10.2217/pgs.14.6
- Bahar MA, Setiawan D, Hak E, Wilffert B. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics 2017;18:701–39. doi: 10.2217/pgs-2017-0194
- Wojtyniak JG, Selzer D, Schwab M, Lehr T. Physiologically based precision dosing approach for drug-drug-gene interactions: a simvastatin network analysis. Clin Pharmacol Ther 2021;109:201–11. doi: 10.1002/cpt.2111
- Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103–41. doi: 10.1016/j.pharmthera.2012.12.007
- Guengerich FP. Intersection of the roles of cytochrome P450 enzymes with xenobiotic and endogenous substrates: relevance to toxicity and drug interactions. Chem Res Toxicol 2017;30:2–12. doi: 10.1021/acs.chemrestox.6b00226
- Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013;13:1–11. doi: 10.1038/tpj.2012.45
- Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Guchelaar H-J, on behalf of the DutchPharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP). Pharmacogenetic information in clinical guidelines: The European perspective. Clin Pharmacol Ther 2018;103:795–801. doi: 10.1002/cpt.1049
- Youssef, E, Kirkdale, CL, Wright, DJ, Guchelaar, H-J, Thornley, T. Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK. Br J Clin Pharmacol 2021;1–19. doi: 10.1111/bcp.14704
- Arjomand-Nahad F, Diefenbach K, Landt O, Gaikovitch E, Roots I. Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes. Anal Biochem 2004;334:201–3. doi: 10.1016/j.ab.2004.07.030
- Steijns LSW, Van Der Weide J. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem 1998;44:914–7. doi: 10.1093/clinchem/44.5.914
- Stuven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 1996;6:417–21. doi: 10.1097/00008571199610000-00005
- Clinical Pharmacogenetics Implementation Consortium (CPIC) [displayed 15 March 2021]. Available at https://cpicpgx.org/guidelines/
- The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG). DPWG Pharmacogenomics guidelines [displayed 30 December 2020]. Available at https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2020.pdf
- Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Croatian Annual Report on Drug Utilisation for 2019 [displayed 30 15 March 2021]. Available at https://www.halmed.hr/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-potrosnji-lijekova
- Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 1997;33:184–213. doi: 10.2165/00003088199733030-00003
- Tang W. The metabolism of diclofenac - enzymology and toxicology perspectives. Curr Drug Metab 2003;4:319–29. doi: 10.2174/1389200033489398
- King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001;61:49–53. doi: 10.1093/toxsci/61.1.49
- Riess W, Stierlin H, Degen P, Faigle JW, Gerardin A, Moppert J, Sallmann A, Schmid K, Schweizer A, Sulc M, Theobald W, Wagner J. Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. Scand J Rheumatol 1978;7(Suppl 22):17–29. doi: 10.3109/03009747809097212
- Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol 2010;77:687–94. doi: 10.1124/mol.109.062364
- Scialis RJ, Aleksunes LM, Csanaky IL, Klaassen CD, Manautou JE. Identification and characterization of efflux transporters that modulate the subtoxic disposition of diclofenac and its metabolites. Drug Metab Dispos 2019;47:1080–92. doi: 10.1124/dmd.119.086603
- Zhang Y, Han YH, Putluru SP, Matta MK, Kole P, Mandlekar S, Furlong MT, Liu T, Iyer RA, Marathe P, Yang Z, Lai Y, Rodrigues AD. Diclofenac and its acyl glucuronide: determination of in vivo exposure in human subjects and characterization as human drug transporter substrates in vitro. Drug Metab Dispos 2016;44:320–8. doi: 10.1124/ dmd.115.066944
- Tomlinson B, Chan P, Zhang Y, Liu Z, Lam CWK. Pharmacokinetics of current and emerging treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol 2020;16:371–85. doi: 10.1080/17425255.2020.1749261
- Iwuchukwu OF, Feng Q, Wei WQ, Jiang L, Jiang M, Xu H, Denny JC, Wilke RA, Krauss RM, Roden DM, Stein CM. Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting. Pharmacogenomics 2014;15:1739–47. doi: 10.2217/pgs.14.128
- Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol 2020;16:809–22. doi: 10.1080/17425255.2020.1801634
- Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med 2019;9(1):22. doi: 10.3390/jcm9010022
- Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 2008;38:1240–51. doi: 10.1080/00498250802334391
- Yasar U, Sain-Guven G, Yardimci Y, Kilicarslan A, Babaoglu MO, Bozkurt A. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients. Basic Clin Pharmacol Toxicol 2 0 1 1 ; 1 0 9 : 7 3 – 7 . doi: 10.1111/j.1742-7843.2011.00687.x
- Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G, Duggan DE. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990;18:476–83. PMID: 1976071
- Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141–60. doi: 10.2165/00003088200342130-00005
- Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, Loi C-M. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos 2007;35:1315–24. doi: 10.1124/dmd.107.015230
- Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, Zanger UM. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 2010;87:65–73. doi: 10.1038/clpt.2009.181
- Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, Baillie TA. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505–12. doi: 10.1124/dmd.30.5.505
- Wei WQ, Feng Q, Jiang L, Waitara MS, Iwuchukwu OF, Roden DM, Jiang M, Xu H, Krauss RM; Rotter JI, Nickerson DA, Davis RL, Berg RL, Peissig PL, McCarty CA, Wilke RA, Denny JC. Characterization of statin dose response in electronic medical records. Clin Pharmacol Ther 2014;95:331–8. doi: 10.1038/clpt.2013.202
- Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008;84:457–61. doi: 10.1038/clpt.2008.25
- Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009;86:197–203. doi: 10.1038/clpt.2009.79
- Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010;87:130–3. doi: 10.1038/ clpt.2009.197
- Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, Schwab M, Schaeffeler E. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med 2013;5(1):1. doi: 10.1186/gm405
- Moßhammer D, Schaeffeler E, Schwab M, Mörike K. Mechanisms and assessment of statin-related muscular adverse effects. Br J Clin Pharmacol 2014;78:454–66. doi: 10.1111/bcp.12360
- Cascorbi I, Haenisch S. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol 2010;596:95–121. doi: 10.1007/978-1-60761-416-6_6
- Nie Y, Yang J, Liu S, Sun R, Chen H, Long N, Jiang R, Gui C. Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics. Xenobiotica 2020; 50: 297 – 317 . doi: 10.1080/00498254.2019.1629043
- Menassé R, Hedwall PR, Kraetz J, Pericin C, Riesterer L, Sallmann A, Ziel R, Jaques R. Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol 1978;7(Suppl 22):5–16. doi: 10.3109/03009747809097211
- Kim G-H. Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press 2008;6:35–41. doi: 10.5049/EBP.2008.6.1.35
- Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106(5B):13S-24S. doi: 10.1016/s0002-9343(99)00113-8
- John CM, Shukla R, Jones CA. Using NSAID in volume depleted children can precipitate acute renal failure. Arch Dis Child 2007;92:524–6. doi: 10.1136/adc.2006.103564
- Zi J, Liu D, Ma P, Huang H, Zhu J, Wei D, Yang J, Chen C. Effects of CYP2C9*3 and CYP2C9*13 on diclofenac metabolism and inhibition-based drug-drug interactions. Drug Metab Pharmacokinet 2010;25:343–50. doi: 10.2133/ dmpk.dmpk-10-rg-009
- Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N, Katori N, Hasegawa R, Yasuda K, Kamide K, Miyata T, Saito Y, Sawada J. Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug Metab Dispos 2009;37:1895–903. doi: 10.1124/dmd.109.027003
- Xia M-M, Wang L, PAan P-P, Wang H-Y, Chen M-C, Chen Y, Dai D-P, Cai J-P, Hu G-X. The role of CYP2C9 genetic polymorphisms in the oxidative metabolism of diclofenac in vitro. Pharmazie 2014;69:898–903. PMID: 25951663
- Dorado P, Cavaco I, Cáceres MC, Piedade R, Ribeiro V, Llerena A. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol 2008;64:967–70. doi: 10.1007/s00228-008-0508-4
- Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmöller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003;55:51–61. doi: 10.1046/j.1365-2125.2003.01712.x
- Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther 2020;108:191–200. doi: 10.1002/ cpt.1830
- Shahabi P, Siest G, Meyer UA, Visvikis-Siest S. Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. Pharmacol Ther 2014;144:134–61. doi: 10.1016/j.pharmthera.2014.05.011
- Capdevila JH, Wang W, Falck JR. Arachidonic acid monooxygenase: Genetic and biochemical approaches to physiological/pathophysiological relevance. Prostaglandins Other Lipid Mediat 2015;120:40–9. doi: 10.1016/j. prostaglandins.2015.05.004
- Fan F, Roman RJ. Effect of cytochrome P450 metabolites of arachidonic acid in nephrology. J Am Soc Nephrol 2017;28:2845–55. doi: 10.1681/ASN.2017030252
- Fan F, Ge Y, Lv W, Elliott MR, Muroya Y, Hirata T, Booz GW, Roman RJ. Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology. Front Biosci (Landmark Ed) 2016;21:1427–63. PMCID: PMC5064940
- Dey A, Maric C, Kaesemeyer WH, Zaharis CZ, Stewart J, Pollock JS, Imig JD. Rofecoxib decreases renal injury in obese Zucker rats. Clin Sci (Lond) 2004;107:561–70. doi: 10.1042/CS20040125
- Sausville LN, Gangadhariah MH, Chiusa M, Mei S, Wei S, Zent R, Luther JM, Shuey MM, Capdevila JH, Falck JR, Guengerich FP, Williams SM, Pozzi A. The cytochrome P450 slow metabolizers CYP2C9*2 and CYP2C9*3 directly regulate tumorigenesis via reduced epoxyeicosatrienoic acid production. Cancer Res 2018;78:4865–77. doi: 10.1158-0008-5472.CAN-17-3977
- Imig JD. Epoxyeicosatrienoic acids, hypertension, and kidney injury. Hypertension 2015;65:476–82. doi: 10.1161/HYPERTENSIONAHA.114.03585
- Imig JD, Khan MAH. Cytochrome P450 and lipoxygenase metabolites on renal function. Compr Physiol 2015;6:423–41. doi: 10.1002/cphy.c150009
- Das A, Weigle AT, Arnold WR, Kim JS, Carnevale LN, Huff HC. CYP2J2 molecular recognition: a new axis for therapeutic design. Pharmacol Ther 2020;215:107601. doi: 10.1016/j.pharmthera.2020.107601
- Wang SY, Xing PF, Zhang CY, Deng BQ. Association of CYP2J2 gene polymorphisms with ischemic stroke and stroke subtypes in Chinese population. Medicine (Baltimore) 2017;96(10):e6266. doi: 10.1097/MD.0000000000006266
- Jarrar YB, Cha E-Y, Seo K-A, Ghim J-L, Kim H-J, Kim D-H, Lee S-J, Shin J-G. Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation. J Lipid Res 2014;55:2334–42. doi: 10.1194/jlr.M051169
- Ward NC, Puddey IB, Hodgson JM, Beilin LJ, Croft KD. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radic Biol Med 2005;38:1032–6. doi: 10.1016/j.freeradbiomed.2004.12.024
- Holthe M, Rakvåg TN, Klepstad P, Idle JR, Kaasa S, Krokan HE, Skorpen F. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 2003;3:17–26. doi: 10.1038/sj.tpj.6500139
- Daly AK, Aithal GP, Leathart JBS, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007;132:272–81. doi: 10.1053/j.gastro.2006.11.023
- Jarrar YB, Kim DH, Lee SJ, Shin JG. Inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) glucuronidation by non-steroidal anti-inflammatory drugs in human liver microsomes and recombinant UDP-glucuronosyltransferase enzymes. Prostaglandins Leukot Essent Fatty Acids 2020;153:102055. doi: 10.1016/j.plefa.2020.102055
- Lazarska KE, Dekker SJ, Vermeulen NPE, Commandeur JNM. Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism. Toxicol Lett 2018;284:70–8. doi: 10.1016/j.toxlet.2017.11.038
- Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998;26:73–7. PMID: 9443856
- Bélanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009;37:1793–6. doi: 10.1124/dmd.109.027706
- Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW. 3’-azido-3’-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000;28:497–502. PMID: 10772627
- Wang H, Yuan L, Zeng S. Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochem Pharmacol 2011;82:1757–63. doi: 10.1016/j.bcp.2011.08.004
- Duguay Y, Báár C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004;75:223–33. doi: 10.1016/j.clpt.2003.10.006
- Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, Bélanger A, Guillemette C. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 2006;66:125–33. doi: 10.1158/0008-5472.CAN-05-2857
- Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe’er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB, on behalf of the Drug-Induced Liver Injury Network, DILIGEN, EUDRAGENE, the Spanish DILI Registry, and the International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012;22:784–95. doi: 10.1097/FPC.0b013e3283589a76
- Lagas JS, van der Kruijssen CM, van de Wetering K, Beijnen JH, Schinkel AH. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos 2009;37:129–36. doi: 10.1124/dmd.108.02320.
- Daly AK. Are polymorphisms in genes relevant to drug disposition predictors of susceptibility to drug-induced liver injury? Pharm Res 2017;34:1564–9. doi: 10.1007/s11095-016-2091-1
- Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W, Kroemer HK, Warzok RW, Cascorbi I. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 2007;7:56–65. doi: 10.1038/sj.tpj.6500403
- Saku K, Zhang B, Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J 2011;75:1493–505. doi: 10.1253/circj. cj-10-1281
- Ooba N, Sato T, Wakana A, Orii T, Kitamura M, Kokan A, Kurata H, Shimodozono Y, Matsui K, Yoshida H, Yamaguchi T, Kageyama S, Kubota K. A prospective stratified case-cohort study on statins and multiple adverse events in Japan. PLoS One 2014;9(5):e96919. doi: 10.1371/journal. pone.0096919
- Staud F, Ceckova M, Micuda S, Pavek P. Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol 2010;596:199–222. doi: 10.1007/978-1-60761-416-6_10
- Duman I. Role of pharmacogenetics on response to statins: a genotype-based approach to statin therapy outcome. J Cardiol Ther 2014;1:111–20. doi: 10.6051/j.issn.2309-6861.2014.01.35
- Zubiaur P, Benedicto MD, Villapalos-García G, Navares-Gómez M, Mejía-Abril G, Román M, Martín-Vílchez S, Ochoa D, Abad-Santos F. SLCO 1B1 phenotype and CYP3A5 polymorphism significantly affect atorvastatin bioavailability. J Pers Med 2021;11:1–15. doi: 10.3390/jpm11030204
- Fukunaga K, Nakagawa H, Ishikawa T, Kubo M, Mushiroda T. ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. BMC Genet 2016;17:79. doi: 10.1186/s12863-016-0390-5
- Gandelman K, Fung GL, Messig M, Laskey R. Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Am J Ther 2012;19:164–73. doi: 10.1097/MJT.0b013e3181f28fb5
- Karaca RO, Kalkisim S, Altinbas A, Kilincalp S, Yuksel I, Goktas MT, Yasar U, Bozkurt A, Babaoglu MO. Effects of genetic polymorphisms of cytochrome P450 enzymes and MDR1 transporter on pantoprazole metabolism and Helicobacter pylori eradication. Basic Clin Pharmacol Toxicol 2017;120:199–206. doi: 10.1111/bcpt.12667
- Safar Z, Kis E, Erdo F, Zolnerciks JK, Krajcsi P. ABCG2/ BCRP: variants, transporter interaction profile of substrates and inhibitors. Expert Opin Drug Metab Toxicol 2019;15:313–28. doi: 10.1080/17425255.2019.1591373
- Hu M, To KKW, Mak VWL, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin Drug Metab Toxicol 2011; 7:49 – 62. doi: 10.1517/17425255.2011.538383
- Tsamandouras N, Guo Y, Wendling T, Hall S, Galetin A, Aarons L. Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population. Pharmacogenet Genomics 2017;27:27–38. doi: 10.1097/FPC.0000000000000252
- Mirosevic Skvrce N, Macolic Sarinic V, Simic I, Ganoci L, Muacevic Katanec D, Bozina N. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. Pharmacogenomics 2015;16:803–15. doi: 10.2217/pgs.15.47
- US Food and Drug Administration. Clinical Drug Interaction Studies - Study Design, Data Analysis, and Clinical Implications. Guidance for Industry [displayed 30 April 2021]. Available at https://www.fda.gov/drugs/drug-interactions-labeling/drug-interactions-relevant-regulatory-guidance-and-policy-documents
- European Medicines Agency. Guideline on the investigation of drug interactions CPMP/EWP/560/95/rev. 1 Corr. 2**. Committee for Human Medicinal Products (CHMP) [displayed 30 April 2021]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/%0AWC500129606.pdf
- Endres CJ, Hsiao P, Chung FS, Unadkat JD. The role of transporters in drug interactions. Eur J Pharm Sci 2006;27:501–17. doi: 10.1016/j.ejps.2005.11.002
- Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstøl K. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006;79:532–9. doi: 10.1016/j. clpt.2006.02.014
- Stormo C, Bogsrud MP, Hermann M, Åsberg A, Piehler AP, Retterstøl K, Kringen MK. UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther 2013;17:233–7. doi: 10.1007/s40291-013-0031-x
- Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One 2011;6(12):e28124. doi: 10.1371/journal.pone.0028124
- Chang C-H, Kusama M, Ono S, Sugiyama Y, Orii T, Akazawa M. Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information. BMJ Open 2013;3(4):e002040. doi: 10.1136/bmjopen-2012-002040
- Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1. Clin Pharmacol Ther 2012;92:584–98. doi: 10.1038/clpt.2012.163
- National Center for Biotechnology Information. Reference SNP (rs) Report [displayed 30 April 2021]. Available at https://www.ncbi.nlm.nih.gov/snp/rs4149056#frequency_tab
- Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, Di Biase M, Brunetti ND. Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vasc Health Risk Manag 2017;13:29–41. doi: 10.2147/VHRM.S95044
- Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li C, Eisenhandler R, Carlini EJ. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 2005;22:71–8. doi: 10.1007/s11095-004-9011-5
- Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006;5:145–56. doi: 10.1517/14740338.5.1.145
- Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis A, Laufer R, Hochman JH, Prueksaritanont T, Lin JH. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 2005; 35: 737 – 53 . doi: 10.1080/00498250500136676
- Poruba M, Matuskova Z, Hüttl M, Malinska H, Oliyarnyk O, Markova I, Gurska S, Kazdova L, Vecera R. Fenofibrate decreases hepatic P-glycoprotein in a rat model of hereditary hypertriglyceridemia. Front Pharmacol 2019;10:56. doi: 10.3389/fphar.2019.00056
- Wen X, Wang J-S, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002;30:631–5. doi: 10.1124/dmd.30.6.631
- Turner RM, Fontana V, FitzGerald R, Morris AP, Pirmohamed M. Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention. Br J Clin Pharmacol 2020;86:62–74. doi: 10.1111/bcp.14133
- Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821–7. doi: 10.1124/dmd.32.8.821
- Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001;364:551–7. doi: 10.1007/s00210-001-0489-715
- Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004;96:1702–13. doi: 10.1093/jnci/djh305
- Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005;156:319–29. doi: 10.1016/j.toxlet.2004.12.008
- Nakaharai K, Sakamoto Y, Yaita K, Yoshimura Y, Igarashi S, Tachikawa N. Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score. Eur J Clin Pharmacol 2016;72:1003–11. doi: 10.1007/s00228-016-2064-7
- Ebner T, Ishiguro N, Taub ME. The use of transporter probe drug cocktails for the assessment of transporter-based drug-drug interactions in a clinical setting-proposal of a four component transporter cocktail. J Pharm Sci 2015;104:3220–8. doi: 10.1002/jps.24489
- Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol 2007;18:37–45. doi: 10.1681/ ASN.2005090966
- Klarica Domjanović I, Lovrić M, Trkulja V, Petelin-Gadže Ž, Ganoci L, Čajić I, Božina N. Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol 2018;84:2106–19. doi: 10.1111/bcp.13646